Adenosine Cardioplegia; Improved Cardioprotection?
- Registration Number
- NCT01123525
- Lead Sponsor
- University Hospital of North Norway
- Brief Summary
60 elective patients for CABG will be included to receive either standard hyperkalemic cardioplegia (St.Thomas Hospital Solution No I) or cardioplegia where supranormal potassium is replaced with 1.2 mM adenosine. Hypothesis as follows: 1. Adenosine instead of supranormal potassium in the cardioplegic solution give satisfactory cardiac arrest. 2. Adenosine instead of supranormal potassium in the cardioplegic solution gives equal cardioprotection. The patients will be followed with PiCCO-catheter to monitor cardiac function and repetitive blood samples to measure release of cardiac enzymes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Elective patients
- Ejection fraction > 40%
- Age 40-75
- No release og TnT or CKMB within last week before CABG
- Pure CABG
- Age >75 or < 40
- EF < 40%
- Emergency operations
- Unstable angina
- Release of TnT or CKMB within the week before operation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Adenosine cardioplegia Adenosine Adenosine cardioplegia Control Adenosine Standard hyperkalemic cardioplegia
- Primary Outcome Measures
Name Time Method Release of cardiac enzymes (TnT and CKMB) First 48 hour postoperatively Repeatedly measured postoperatively.
- Secondary Outcome Measures
Name Time Method PiCCO First 24 hours postoperatively Measurement of cardiac function and hemodynamics the first 24 hours postoperatively
Endothelial injury Peroperatively (before crossclamping aorta and after 5 minutes of reperfusion) Measurements of markers of endothelial injury/dysfunction peroperatively. Blood will be sampled immediately before cross-clamping the aorta and after 5 minutes of reperfusion.
Trial Locations
- Locations (1)
University Hospital of North Norway
🇳🇴Troomsø, Norway